Balyasny Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Balyasny Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-17,400	Closed	-$193K	–	2451
2017 Q3	$193K	Buy	+17,400	New	+$164K	﹤0.01%	1718
2016 Q1	–	Sell	-14,230	Closed	-$90K	–	1626
2015 Q4	$90K	Buy	+14,230	New	+$115K	﹤0.01%	1171
2015 Q1	–	Sell	-149,477	Closed	-$2.55M	–	1131
2014 Q4	$2.55M	Buy	+149,477	New	+$2.16M	0.02%	529

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Balyasny Asset Management's STML Position: Q4 2017 in Review

Balyasny Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 17,400 shares — an estimated $193K sold.

Balyasny Asset Management first reported a position in STML in Q4 2014 and held it in 3 quarters. The position peaked at $2.55M in Q4 2014. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

Balyasny Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Balyasny Asset Management sold 17,400 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $193K.
Balyasny Asset Management first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
Balyasny Asset Management's Stemline Therapeutics, Inc. position peaked at $2.55M in Q4 2014.
80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.